Baron Wealth Management LLC trimmed its holdings in McKesson Co. (NYSE:MCK – Free Report) by 3.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 499 shares of the company’s stock after selling 20 shares during the quarter. Baron Wealth Management LLC’s holdings in McKesson were worth $284,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Old North State Trust LLC raised its holdings in McKesson by 1.6% in the 3rd quarter. Old North State Trust LLC now owns 1,138 shares of the company’s stock valued at $563,000 after acquiring an additional 18 shares in the last quarter. Trust Co. of Vermont raised its stake in shares of McKesson by 4.8% in the fourth quarter. Trust Co. of Vermont now owns 393 shares of the company’s stock valued at $224,000 after purchasing an additional 18 shares in the last quarter. Black Diamond Financial LLC boosted its stake in McKesson by 1.3% during the third quarter. Black Diamond Financial LLC now owns 1,525 shares of the company’s stock worth $754,000 after buying an additional 19 shares in the last quarter. QV Investors Inc. increased its holdings in McKesson by 0.6% in the 3rd quarter. QV Investors Inc. now owns 3,499 shares of the company’s stock valued at $1,730,000 after buying an additional 20 shares during the period. Finally, ASB Consultores LLC raised its stake in shares of McKesson by 2.4% in the 3rd quarter. ASB Consultores LLC now owns 879 shares of the company’s stock valued at $435,000 after buying an additional 21 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.
McKesson Stock Performance
MCK opened at $603.79 on Thursday. The company has a fifty day moving average price of $592.16 and a two-hundred day moving average price of $561.52. The firm has a market capitalization of $76.64 billion, a PE ratio of 31.27, a P/E/G ratio of 1.26 and a beta of 0.52. McKesson Co. has a 52 week low of $464.42 and a 52 week high of $637.51.
Analyst Ratings Changes
MCK has been the subject of several recent research reports. StockNews.com raised shares of McKesson from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Wells Fargo & Company boosted their price target on McKesson from $535.00 to $641.00 and gave the company an “equal weight” rating in a research note on Friday, December 13th. Leerink Partners dropped their price objective on McKesson from $665.00 to $630.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Robert W. Baird upgraded shares of McKesson from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $531.00 to $688.00 in a research report on Thursday, November 7th. Finally, Morgan Stanley boosted their price target on shares of McKesson from $612.00 to $642.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Two investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and a consensus price target of $646.14.
Read Our Latest Stock Report on McKesson
Insider Buying and Selling
In other news, EVP Leann B. Smith sold 579 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total transaction of $331,645.41. Following the sale, the executive vice president now owns 864 shares of the company’s stock, valued at $494,890.56. This trade represents a 40.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.11% of the stock is owned by insiders.
About McKesson
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Read More
- Five stocks we like better than McKesson
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 5 Stocks With Above-Market Yields Just Raised Payments Further
- Best Stocks Under $5.00
- Arista Networks’ Stock Plunge: Buying Opportunity for Investors?
- Most active stocks: Dollar volume vs share volume
- As China Tightens Rare Earth Exports, These 3 Stocks Are in Focus
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.